Stockscreener 앱 받기
60.22
0.89%
0.53
시장 영업 전:
60.99
0.77
+1.28%
전일 마감가:
$59.69
열려 있는:
$60
하루 거래량:
536.01K
Relative Volume:
0.32
시가총액:
$6.46B
수익:
$769.10M
순이익/손실:
$46.67M
주가수익비율:
172.06
EPS:
0.35
순현금흐름:
$119.79M
1주 성능:
+6.83%
1개월 성능:
+29.31%
6개월 성능:
-22.09%
1년 성능:
-20.86%
1일 변동 폭
$59.54
$60.95
1주일 범위
$54.59
$60.95
52주 변동 폭
$28.66
$91.00
코르셉트 테라퓨틱스 Stock (CORT) Company Profile
명칭
Corcept Therapeutics Inc
전화
650.688.8803
주소
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
60.22 | 6.41B | 769.10M | 46.67M | 119.79M | 0.35 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
코르셉트 테라퓨틱스 Stock (CORT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-26 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-12-31 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2025-12-16 | 개시 | UBS | Neutral |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2023-11-06 | 업그레이드 | Truist | Hold → Buy |
| 2023-04-11 | 개시 | SVB Securities | Market Perform |
| 2023-04-04 | 개시 | Piper Sandler | Overweight |
| 2023-02-15 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-08-01 | 다운그레이드 | Truist | Buy → Hold |
| 2022-07-27 | 업그레이드 | Jefferies | Hold → Buy |
| 2022-06-27 | 재개 | Canaccord Genuity | Buy |
| 2022-02-02 | 개시 | Canaccord Genuity | Buy |
| 2022-01-28 | 개시 | Truist | Buy |
| 2020-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2019-09-24 | 개시 | Jefferies | Buy |
| 2019-09-06 | 개시 | H.C. Wainwright | Buy |
| 2019-02-04 | 다운그레이드 | B. Riley FBR | Buy → Neutral |
| 2018-08-10 | 재확인 | Stifel | Hold |
| 2018-05-31 | 다운그레이드 | Stifel | Buy → Hold |
| 2018-03-09 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-08-31 | 개시 | Stifel | Buy |
| 2017-02-02 | 개시 | Ladenburg Thalmann | Buy |
| 2015-04-21 | 개시 | FBR Capital | Outperform |
| 2014-01-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2013-08-09 | 다운그레이드 | Janney | Buy → Neutral |
| 2013-08-09 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2012-02-21 | 재확인 | JMP Securities | Mkt Outperform |
| 2010-01-06 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2008-07-17 | 개시 | Rodman & Renshaw | Mkt Outperform |
| 2007-06-21 | 업그레이드 | Punk, Ziegel & Co | Mkt Perform → Accumulate |
모두보기
코르셉트 테라퓨틱스 주식(CORT)의 최신 뉴스
CORT Stock Price, Quote & Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
Affiliate of CORT (NASDAQ: CORT) files Form 144 to offer 5,000 shares - Stock Titan
Wall Street Analysts Believe Corcept (CORT) Could Rally 43.32%: Here's is How to Trade - Yahoo Finance UK
Corcept Therapeutics Inc. (CORT) Stock Analysis: Exploring a 40.15% Potential Upside for Biotech Investors - DirectorsTalk Interviews
Corcept (CORT) chief business officer reports 7,300-share gift of common stock - Stock Titan
CORT Stock Chart | CORCEPT THERAPEUTICS INC (NASDAQ:CORT) - ChartMill
UBS upgrades Corcept Therapeutics (CORT) - MSN
Corcept Therapeutics (CORT) Receives Upgrade, Stock Surges Over 7% - GuruFocus
Corcept Therapeutics Shares Rise After UBS Upgrade - Moomoo
UBS Upgrades Corcept Therapeutics(CORT.US) to Buy Rating, Cuts Target Price to $72 - Moomoo
Corcept Therapeutics climbs on UBS upgrade - MSN
Corcept Therapeutics (CORT) Stock Analysis: Unveiling a 40% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
CORT Q1 earnings match estimates, revenues miss, 2026 outlook raised - MSN
Vanguard Group Inc. Has $330.42 Million Holdings in Corcept Therapeutics Incorporated $CORT - MarketBeat
Why Corcept Therapeutics Stock Is Sinking Now - TipRanks
CORT IMPORTANT DEADLINE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept (CORT) CDO sells 20K shares under 10b5-1 plan - Stock Titan
CORT FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept Therapeutics (CORT) Is Up 11.9% After Q1 Loss, Higher 2026 Outlook And ALS DataHas The Bull Case Changed? - Yahoo Finance
Corcept (CORT) Q1 2025 Earnings Transcript - AOL.com
Corcept Must Face Most Teva Mifepristone Antitrust Claims - Law360
Corcept Therapeutics IncorporatedCommon Stock (NQ: CORT - FinancialContent
How many employees work at Corcept Therapeutics? - Revelio Labs
Teva's US exclusive-dealing claims survive Corcept's move to dismiss - MLex
Corcept (NASDAQ: CORT) CEO sells 40K shares under 10b5-1 plan - Stock Titan
Corcept Therapeutics (NASDAQ: CORT) affiliate plans sale of 20,000 shares via Stifel - Stock Titan
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2026 Earnings Call Transcript - Insider Monkey
CORT Q1 Deep Dive: Early Lifyorli Launch and Endocrinology Momentum Offset Margin Pressures - Yahoo Finance
Corcept (CORT) Q1 2026 Earnings Transcript - AOL.com
Corcept Therapeutics Is Maintained at Buy by HC Wainwright & Co. - Moomoo
CCORF Maintains Corcept Therapeutics(CORT.US) With Buy Rating, Maintains Target Price $110 - Moomoo
Corcept (CORT) Q2 2025 Earnings Transcript - AOL.com
Corcept (CORT) Q4 2025 Earnings Transcript - AOL.com
CORT Maintained by HC Wainwright & Co. -- Price Target Raised to $75 - GuruFocus
CORT DEADLINE: ROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Corcept Therapeutics Incorporated Investors with Losses in Excess of $100K to Secure Counsel Before Important April 21 Deadline in Securities Class ActionCORT - TMX Newsfile
Corcept Therapeutics Inc. (CORT) Stock Analysis: A 36.91% Upside Potential In Biotech - DirectorsTalk Interviews
MSN Money - MSN
symbol__ Stock Quote Price and Forecast - CNN
Corcept (CORT) Upgraded After Key Regulatory Approval for Lifyorli - Yahoo Finance
Corcept Therapeutics Shakes Up Nasdaq Index Fund Radar - Kalkine Media
CORT Maintained by Piper Sandler -- Price Target Raised to $88 - GuruFocus
Corcept Therapeutics Guides Higher on Lifyorli-Fueled Revenue Growth - The Globe and Mail
Corcept Therapeutics Is Maintained at Overweight by Piper Sandler - Moomoo
Corcept Therapeutics (NASDAQ:CORT) Stock Price Up 7.9%Time to Buy? - MarketBeat
Corcept Therapeutics (CORT) insider notifies sale of 40,000 shares via Stifel - Stock Titan
CORT Q1 Earnings Match Estimates, Revenues Miss, 2026 Outlook Raised - The Globe and Mail
Corcept Therapeutics Pivotal Study Shows 87% Lower Death Risk - Benzinga
Corcept Therapeutics Incorporated Q1 2026 Earnings Call Summary - Yahoo Finance
Corcept Therapeutics Inc (CORT) Q1 2026 Earnings Call Highlights - GuruFocus
코르셉트 테라퓨틱스 (CORT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.98%
1.33%
자본화:
|
볼륨(24시간):